In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …

Tumor microenvironments (TMEs) influence cancer progression but are complex and often
differ between patients. Considering that microenvironment variations may reveal rules …

The concept of targeting cholesterol metabolism to treat cancer has been widely tested in
clinics, but the benefits are modest, calling for a complete understanding of cholesterol …

Head and neck squamous cell carcinoma (HNSCC) undergoes stepwise progression from
normal tissues to precancerous leukoplakia, primary HNSCC, and metastasized tumors. To …

As the essential regulators of organ fibrosis, macrophages undergo marked phenotypic and
functional changes after organ injury. These changes in macrophage phenotype and …

Tumor-associated macrophages (TAMs) are pivotal in cancer progression, influencing tumor
growth, angiogenesis, and immune evasion. This review explores the spatial and temporal …

Myeloid cells facilitate T cell immune evasion in cancer yet are pliable and have antitumor
potential. Here, by cotargeting myeloid activation molecules, we leveraged the myeloid …

Enoblituzumab, an immunotherapeutic agent targeting CD276, shows both safety and
efficacy in activating T cells and oligodendrocyte-like cells against various cancers …

There is a pressing need to improve risk stratification and treatment selection for HPV-
negative head and neck squamous cell carcinoma (HNSCC) due to the adverse side effects …